Couldn't make it to Denver for the AAD conference? Made it to Denver but maybe had one too many Old Fashions to make it to the late breaking abstract presentations? DoD may have had too many Old Fashions (it was really only Dr. Zirwas), but we still made it to the session with all the hottest data in the world of dermatology. Join Drs. Zirwas, Ferris, and Patton for the first episode of this pair that'll keep you ahead of the curve.

Get ready for the Derms on Drugs to tackle the tough questions in Dermatology. This episode has Matt, Laura, and Tim reviewing 8 papers that span the spectrum, from cutaneous melanoma to the mysteries of melatonin on the skin.

The Derms on Drugs get schooled on Hidradenitis Suppurativa by Dr. Chris Sayed from the University of North Carolina. This will be one of the most practically useful sessions you've ever heard as we go way beyond the basics - we go way beyond basics like the biologics that don't work all that well.
We'll get into a bunch of questions you probably haven't hear discussed with HS before:
- What's the window of opportunity in HS and how do you keep it open?
- Is there any such thing as mild HS?
- What antibiotics actually work for HS and how do you use them?
- Do ancillary treatments like spironolactone, metronidazole and oral roflumilast actually move the needle in a meaningful way?
- If you're going to learn one surgical technique to really help your HS patients which procedure should you pick and how should you learn it?
- What will be the likely role of JAK Inhibitors in HS?
- Is it actually possible to get patients with long term, scarring severe HS better?

Melanoma, extramammary paget's and a prostate cancer drug walk into a bar... well, it may sound like a joke, but this week's episode is no laughing matter! Join the Derms on Drugs as we get into some deep topics:
New data on Castle Gene Expression Profiling for thin melanomas - does it finally answer the age old question question: To send or not to send?
Did you know that as we get older, our lymphatics get leaky and it is actually pretty important when it comes to melanoma?
Extramammary Paget's Disease (EMPD) is a bad actor - when you see it, what should you do about it? Wide local excision vs Mohs vs Mohs plus radiation?
You know Dr. Patton's a nerd. But this week is off the charts. You'll learn more about pathological staining of EMPD that you ever wanted.
Bicaludamide? Better than spironolactone for female pattern hair loss? What do you need to know to start prescribing it?
Pruritus in renal failure patients is the WORST, turns out that medications can be a big driving factor and stopping them might be all you need to do.

Matt, Laura, and Tim are joined by Dr. Lauren Graham (UAB) for a deep dive into cutaneous connective tissue disease. They cover the latest in lupus treatment — including the game-changing anifrolumab and its emerging sub-Q formulation — plus dermatomyositis workup, malignancy screening, the buzz around brepocitinib, and whether roflumilast deserves a spot as first-line therapy.

The Derms on Drugs are back it, answering the burning questions you didn't know you had. This week's hot topics:
Aviclear laser new data just dropped. Realistic alternative to Accutane or just another device that sits in the corner and gathers dust?
Does mycophenolate actually do anything in pemphigus?
More data about Dupixent, CTCL and cancer. Does it help, hurt or it's a wash?
What happens if you get scabies while you're on Dupixent? Turns out Zirwas has been wrong about this for years.
Who is at risk for hyperkalemia on spironolactone and is it bad enough that we should care?
Our goal in early hidradenitis is to prevent progression to scarring - what factors that predict who is likely to progress and what can prevent it?
There's a new side effect to worry about with JAK inhibitors and we promise you won't forget about it.
Finally, what do you say when a patient says "What would you do?"

Big news on TB Tests for psoriasis patients on biologics! New official recommendations say not necessary for IL-17s and IL-23s. Literally zero cases. Ever.
Think nicotinamide prevents skin cancer? Think again. Not saying it doesn't, but turns out data isn't really there and the jury is still out.
How safe are topical steroids? Depends. Depends what else you're taking, especially NSAIDS - turns out it may increase your risk of an upper GI pretty substantially.
If somebody doesn't respond adequately to Dupixent, what happens if you switch them to Rinvoq? Abbvie kind of answered the question, but not really.
Just how well does Rhapsido work in CSU? And does it actually cause bleeding? No, no it does not. But we're understanding more and more about why it causes petechiae.
Are PDE4 inhibitors like apremilast and roflumilast effective for bullous pemphigoid? Maybe.
Do Sotyktu (and the new TYK2 inhibitors coming soon) work for atopic dermatitis? We got our first data and it looks like they are pretty great.

The Derms on Drugs are back at it, answering the burning derm questions you didn't even know you had. Join us this week as we dive into more "outside the box" therapies that you can use next week in the office.
-Is low dose naltrexone a lifeline in difficult dermatoses or a false hope?
-There's been some chatter around metformin for hidradenitis suppurativa. Is it hype or hope?
-Diet and chronic spontaneous urticaria - Patients always ask and while we know it isn't food allergy, new data says that diet does play a role and gives us a simple intervention that's worth trying.
-Everybody hates warts and we're always looking for pain free treatment options - could a heating pad and hydrogen peroxide be the answer?
-Can we knock out psoriasis long term with a few months of high dose IL-23 inhibition?
-We love tranexamic acid for melasma, but does oral or topical work better?
-Once a vitiligo patient gets better, can you stop the Opzelura?
-Fact or Fiction: Compared to PLEVA, PLC lasts longer and happens in adults more than kids?